The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

被引:31
作者
Dias, M. M. [1 ]
Pignon, J-P [2 ]
Karapetis, C. S. [3 ]
Boige, V. [4 ]
Glimeliuss, B. [5 ]
Kweekel, D. M. [6 ]
Lara, P. N. [7 ]
Laurent-Puig, P. [8 ]
Martinez-Balibrea, E. [9 ]
Paez, D. [10 ]
Punt, C. J. A. [11 ]
Redman, M. W. [12 ]
Toffoli, G. [13 ]
Wadelius, M. [14 ]
McKinnon, R. A. [3 ]
Sorich, M. J. [1 ,15 ]
机构
[1] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia
[2] Gustave Roussy, Dept Biostat & Epidemiol, Metaanal Unit, Villejuif, France
[3] Flinders Univ S Australia, Sch Med, Flinders Ctr Innovat Canc, Adelaide, SA 5042, Australia
[4] Gustave Roussy, Dept Med Oncol, Villejuif, France
[5] Uppsala Univ, Dept Radiol Oncol & Radiat Sci, Sect Oncol, Uppsala, Sweden
[6] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands
[7] Univ Calif Sacramento, Davis Comprehens Canc Ctr, Sacramento, CA USA
[8] Univ Paris 05, INSERM, Unite Mixte Rech S775, Paris, France
[9] Fdn Inst IGTP, Inst Catala Oncol, Lab Mol Canc Biol, Badalona, Spain
[10] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[11] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands
[12] Fred Hutchinson Canc Res Ctr, Lung & Canc Control Comm, Stat Ctr SWOG, Seattle, WA 98104 USA
[13] Natl Canc Inst, CRO, Expt & Clin Pharmacol Unit, Aviano, Italy
[14] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[15] Flinders Univ S Australia, Sch Med, Dept Clin Pharmacol, Adelaide, SA 5042, Australia
关键词
METASTATIC COLORECTAL-CANCER; DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1; GENOTYPING REDUCE MORBIDITY; DOSE-DEPENDENT ASSOCIATION; COMPREHENSIVE ANALYSIS; INDUCED NEUTROPENIA; COST-EFFECTIVENESS; GENETIC-VARIANTS; POLYMORPHISM; COMBINATION;
D O I
10.1038/tpj.2014.16
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
To date, studies of irinotecan pharmacogenetics have mostly focused on the effect of the UGT1A1*28 allele on irinotecan-related toxicity. However, the clinical utility of routine UGT1A1*28 genotyping to pre-emptively adjust irinotecan dosage is dependent upon whether UGT1A1*28 also affects patient survival following irinotecan therapy. Previous observational studies evaluating the influence of UGT1A1*28 on survival have shown contradictory results. A systematic review and meta-analysis of both published and unpublished data were performed to summarize the available evidence of the relationship between the UGT1A1*28 allele and patient survival related to irinotecan therapy. Overall and progression-free survival meta-analysis data were available for 1524 patients and 1494 patients, respectively. The difference in the survival between patients of different UGT1A1*28 genotypes (homozygous, heterozygous or wild-type) who had received irinotecan was not found to be statistically significant. There was also no evidence of irinotecan dose, regimen or line of therapy having an impact on this association.
引用
收藏
页码:424 / 431
页数:8
相关论文
共 48 条
[1]  
[Anonymous], 2009, INT STAT REV
[2]  
[Anonymous], PLOS MED
[3]   Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? [J].
Berg, Alfred O. ;
Armstrong, Katrina ;
Borkin, Jeffrey ;
Calonge, Ned ;
Haddow, James ;
Hayes, Maxine ;
Kaye, Celia ;
Phillips, Kathryn A. ;
Piper, Margaret ;
Richards, Carolyn Sue ;
Scott, Joan A. ;
Strickland, Ora L. ;
Teutsch, Steven .
GENETICS IN MEDICINE, 2009, 11 (01) :15-20
[4]   Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05 [J].
Boige, Valerie ;
Mendiboure, Jean ;
Pignon, Jean-Pierre ;
Loriot, Marie-Anne ;
Castaing, Marine ;
Barrois, Michel ;
Malka, David ;
Tregouet, David-Alexandre ;
Bouche, Olivier ;
Le Corre, Delphine ;
Miran, Isabelle ;
Mulot, Claire ;
Ducreux, Michel ;
Beaune, Philippe ;
Laurent-Puig, Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) :2556-2564
[5]   Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial [J].
Braun, Michael S. ;
Richman, Susan D. ;
Quirke, Philip ;
Daly, Catherine ;
Adlard, Julian W. ;
Elliott, Faye ;
Barrett, Jennifer H. ;
Selby, Peter ;
Meade, Angela M. ;
Stephens, Richard J. ;
Parmar, Mahesh K. B. ;
Seymour, Matthew T. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) :2690-2698
[6]   Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics - To test or not to test, that is the question [J].
Deeken, John F. ;
Slack, Rebecca ;
Marshall, John L. .
CANCER, 2008, 113 (07) :1502-1510
[7]  
Dias MM, 2012, PHARMACOGENOMICS, V13, P889, DOI [10.2217/PGS.12.68, 10.2217/pgs.12.68]
[8]   Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial [J].
Ducreux, Michel ;
Malka, David ;
Mendiboure, Jean ;
Etienne, Pierre-Luc ;
Texereau, Patrick ;
Auby, Dominique ;
Rougier, Philippe ;
Gasmi, Mohamed ;
Castaing, Marine ;
Abbas, Moncef ;
Michel, Pierre ;
Gargot, Dany ;
Azzedine, Ahmed ;
Lombard-Bohas, Catherine ;
Geoffroy, Patrick ;
Denis, Bernard ;
Pignon, Jean-Pierre ;
Bedenne, Laurent ;
Bouche, Olivier .
LANCET ONCOLOGY, 2011, 12 (11) :1032-1044
[9]   Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism [J].
Font, A ;
Sánchez, JM ;
Tarón, M ;
Martinez-Balibrea, E ;
Sánchez, JJ ;
Manzano, JL ;
Margelí, M ;
Richardet, M ;
Barnadas, A ;
Abad, A ;
Rosell, R .
INVESTIGATIONAL NEW DRUGS, 2003, 21 (04) :435-443
[10]   Systematic review and meta-analysis: When one study is just not enough [J].
Garg, Amit X. ;
Hackam, Dan ;
Tonelli, Marcello .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (01) :253-260